Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

Trial Profile

A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Recurrent Ovarian Cancer or Other Recurrent MUC16+ Cancers

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemiplimab (Primary) ; Ubamatamab (Primary) ; Ubamatamab (Primary)
  • Indications Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; First in man; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals

Most Recent Events

  • 04 Jun 2024 According to a trial design for phase 2 cohort, presented at the 60th Annual Meeting of the American Society of Clinical Oncology, the study is currently enrolling to these OC and EC expansion cohorts.
  • 04 Jun 2024 Trial design for phase 2 cohort, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 29 Mar 2024 Results (n=12) assessing Pharmacokinetics (Pk), Serum Cytokines, and Safety Following Intravenous or Subcutaneous Step Up Dosing of Ubamatamab,in Patients with Recurrent Ovarian Cancer presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top